Pathophysiology and Prevention of Atrial Fibrillation

Maurits A. Allessie(Maastricht University), Penelope A. Boyden(National Heart Lung and Blood Institute), A. John Camm(Maastricht University), André G. Kléber(National Heart Lung and Blood Institute), Max J. Lab(National Heart Lung and Blood Institute), Marianne J. Legato(Imperial College London), Michael R. Rosen(Maastricht University), Peter J. Schwartz(Imperial College London), Peter M. Spooner(St George's Hospital), David R. Van Wagoner(Cleveland Clinic), Albert L. Waldo(University of Bern)
Circulation
February 6, 2001
Cited by 731Open Access
Full Text

Abstract

A trial fibrillation (AF) is a ubiquitous yet diverse cardiac arrhythmia whose incidence increases with age; with most forms of cardiac and some pulmonary diseases; and with a number of metabolic, toxic, endocrine, or genetic abnormalities. Classification of clinical AF subtypes can be achieved on the basis of the ease by which episodes of the arrhythmia terminate as follows 3 : "Paroxysmal" AF refers to episodes that generally stop spontaneously after no more than a few days. "Persistent" AF occurs less frequently than paroxysmal AF and, rather than self-terminating, requires cardioversion to restore sinus rhythm. "Permanent" AF cannot be converted to sinus rhythm. These terms apply strictly to chronic AF, because a single episode of the arrhythmia cannot be fully categorized. Although there are some mixed patterns, they generally derive from physician impatience for early cardioversion or from pragmatic clinical considerations (eg, to avoid thrombus formation or hemodynamic decompensation).


Related Papers

No related papers found

Powered by citation graph analysis